Analyst IMS Investment Management Services Ltd. Sells 1,296 Shares of Eli Lilly and Company $LLY

Analyst IMS Investment Management Services Ltd. lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 43.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,690 shares of the company’s stock after selling 1,296 shares during the quarter. Analyst IMS Investment Management Services Ltd.’s holdings in Eli Lilly and Company were worth $1,317,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of LLY. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $27,000. Blume Capital Management Inc. grew its position in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares during the last quarter. Citizens National Bank Trust Department grew its position in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares during the last quarter. IMG Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $35,000. Finally, Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $40,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $821.60 on Wednesday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The company has a 50 day simple moving average of $772.90 and a two-hundred day simple moving average of $769.79. The stock has a market cap of $777.61 billion, a price-to-earnings ratio of 53.70, a PEG ratio of 1.23 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the previous year, the business posted $3.92 EPS. The business’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.14% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on LLY shares. Leerink Partnrs downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Cantor Fitzgerald set a $925.00 target price on shares of Eli Lilly and Company and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Finally, Guggenheim reissued a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a research report on Thursday, October 16th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $938.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.